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Introduction: Erlotinib, a tyrosine kinase inhibitor, has improved
survival and quality of life in patients with non-small cell lung
cancer (NSCLC) after first- or second-line chemotherapy. Asian
origin, adenocarcinoma histology, female gender, lack of tobacco
use, and expression of epidermal growth factor receptor are signif-
icant independent predictors of response to Erlotinib. Although
tobacco use is considered a major cause of NSCLC, other risk
factors such as wood-smoke exposure (WSE) are associated. Almost
3 billion people worldwide rely on solid fuels as their primary
source of domestic energy for cooking and heating.
Methods: In this study, 150 consecutive unselected patients with
histologically proven NSCLC with progression after prior first- or
second-line chemotherapy and/or poor performance status were
treated with Erlotinib 150 mg/d. Clinical and pathologic character-
istics were associated with response.
Results: Overall response to Erlotinib was observed in 51 patients
[34%; 95% confidence interval {95% CI}, 29.9–37.6]. In multivar-
iate analysis, clinical features associated with response to Erlotinib
were adenocarcinoma (35 versus 20%; p  0.05) and WSE (83
versus 13%; p 0.001). Factors associated with longer progression-
free survival in Cox analysis included adenocarcinoma (7.9 versus
2.3 months; p  0.009), female gender (8.4 versus 5.3 months; p 
0.04), and WSE (17.6 versus 5.3 months; p  0.006).
Conclusions: WSE is associated with better response to Erlotinib
and improved progression-free survival in patients with NSCLC.
Additional studies in epidermal growth factor receptor signaling
pathway in WSE-associated NSCLC are warranted.
Key Words: Erlotinib, Non-small cell lung cancer, Response pre-
dictor, Survival predictor, Wood-smoke exposure.
(J Thorac Oncol. 2008;3: 887–893)
Lung cancer is the leading cause of cancer-related deathsworldwide. In 2007, the estimated incidence in the United
States was 213,380 with 160,390 deaths.1 In 2002, 8044 new
cases and 8255 deaths were reported in Mexico.2 Although
tobacco use is considered a major cause of non-small cell
lung cancer (NSCLC), other etiologic factors have been
proposed for its development, including radon exposure,
cooking fumes, asbestos, heavy metals, human papillomavi-
rus infection, and genetic susceptibility. Wood dust is desig-
nated as a human carcinogen and a risk factor for lung
cancer.3 Wood is burned for heating and cooking or just for
pleasure in many homes worldwide. Almost 3 billion people
rely on solid fuel (biomass and coal) as their primary source
of domestic energy. Most of them live in developing coun-
tries but there are also many living in countries with a cold
climate, such as those in Northern Europe.4 In addition North
Americans, particularly in Canada and the northwestern and
northeastern sections of the United States, have increasingly
turned to woodburning as an alternative method for domestic
heating because of increasing energy costs.4,5
Wood-smoke exposure (WSE) for 50 years has been
associated with increased risk of lung cancer as compared
with pulmonary tuberculosis, interstitial lung disease, and
miscellaneous pulmonary conditions [odds ratio, 1.9; 95%
confidence interval {CI}, 1.1–3.5] after adjusting for age,
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education, socioeconomic status, and tobacco smoke expo-
sure.6 Pathophysiologic mechanisms in the development of
WSE-associated NSCLC remain unknown to date. Wood
byproducts, such as benzene, 1,3-butadiene, formaldehyde
and acetaldehyde are known carcinogens.4 Macrophage dys-
function and increased activity of matrix metalloproteinases,
specifically MMP-2 and -9 have been reported. Several stud-
ies have demonstrated that WSE could increase phospho-p53
protein. These changes could be similar to those caused by
tobacco smoke.7
Chemotherapy, alone or in combination with radiation
therapy, is the standard treatment for advanced NSCLC. With
current first-line platinum-based chemotherapy schemes, me-
dian survival is 7 to 10 months.8–10 Docetaxel or Pemetrexed-
based regimens are the current standard for second-line che-
motherapy in NSCLC, exhibiting a 6 to 9% response rate
(RR) and median survival time of 6 to 8 months.11–13 How-
ever, improvements in chemotherapy for advanced NSCLC
have reached a plateau. Advances in understanding the mo-
lecular basis of cancer biology have led to the discovery of
several potential molecular targets, such as the epidermal
growth factor receptor (EGFR), a tyrosine kinase (TK) re-
ceptor of the ErbB family that is usually altered in epithelial
tumors.14 It mediates cell proliferation, differentiation, sur-
vival, angiogenesis, and migration,15 and is overexpressed in
40 to 80% of NSCLC tumors.16,17 Erlotinib is an orally
active, quinazoline TK inhibitor that specifically targets
EGFR. The BR.21 phase III study compared Erlotinib versus
placebo in patients with stage IIIB/IV NSCLC and one or two
prior chemotherapy regimens, and provided the first evidence
that EGFR inhibitors extend survival in chemotherapy-refrac-
tory NSCLC; patients receiving Erlotinib displayed signifi-
cant longer overall survival (6.7 versus 4.7 months) and
progression-free survival (PFS) (2.2 versus 1.8 months) than
those receiving placebo, with an overall RR of 8.9%. In
addition, a higher RR was observed among specific subpopu-
lations, including women, Asian ethnicity, patients who had
never smoked, and patients with adenocarcinoma.12 More-
over, expression of EGFR by immunohistochemistry or flu-
orescent in situ hybridization is another independent predictor
of response and survival.18 We conducted a prospective study
to identify prognosis-associated predictive factors in patients
treated with Erlotinib in Mexican population.
MATERIALS AND METHODS
Patient Selection
With previous approval by the Institutional and Federal
Health Office Boards (Instituto Nacional de Cancerologı´a and
Secretarı´a de Salud, Mexico, respectively), we enrolled con-
secutive unselected patients with advanced NSCLC partici-
pating in the TRUST study, an open label, nonrandomized
trial initiated to provide erlotinib access to patients with
advanced NSCLC, between August 2005 and March 2007.
One hundred and fifty patients were included from two
national reference centers (Instituto Nacional de Cancerolo-
gia and Instituto Nacional de Enfermedades Respiratorias),
which take care of patients mainly from rural areas of all the
country. All patients gave written informed consent. A com-
plete medical history and physical examination including skin
assessment, complete blood count with differential and plate-
let count, biochemical profile, urinalysis, electrocardiogram,
and computed tomography of chest and abdomen were ob-
tained. Details of WSE, including hours per day and years of
exposure, were also recorded. WSE was defined as being ex-
posed to fumes resulting from burning of wood in fireplaces and
wood stoves for 5 years for at least 4 hours per day.4 We
defined the term non smoker to refer to an individual who has
had a lifetime exposure of less than 100 cigarettes.19
Eligible patients met the following criteria: histologi-
cally or cytologically proven stage IIIB/IV NSCLC; Eastern
Cooperative Oncology Group (ECOG) performance status 0
to 3; progression to one or two prior chemotherapy regimens
or being considered unsuitable to receive standard chemo-
therapy or radiotherapy; age 18 years; ability to swallow
tablets; adequate laboratory measurements (WBC 1,500/
mm3, hemoglobin 10.0 g/dl, platelet count 100,000/mm3,
total bilirubin 1.5 mg/dl, aspartate aminotransferase 2.0
mg/dl upper limit of normal; creatinine 1.5 mg/dl); for
females in childbearing age, negative pregnancy test within
72 hours of enrollment; measurable disease according to
Response Evaluation Criteria in Solid Tumors (RECIST), and
life expectancy of 12 weeks.
Patients with known central nervous system metastases
were eligible provided that at least 2 months had elapsed
since completion of radiation therapy. Patients with prior
treatment with any EGFR-targeted agent, major surgery or
radiation therapy within the last 21 days, any active gastro-
intestinal disorder that alters motility or absorption, and
severe and unstable medical comorbidities were ineligible.
Treatment Plan
Erlotinib was administered within 2 days after screen-
ing in an open-labeled fashion to all patients. Patients had to
have recovered from any toxic effect of previous treatments
and at least 21 days had passed after any previous chemo-
therapy regimen. All patients received an initial dose of 150
mg per day; each cycle had a duration of 4 weeks. Physical
examination and hematologic and biochemical testing were
performed in every cycle. Response assessment was per-
formed after every two protocol-treatment cycles according
to RECIST criteria. National Cancer Institute Common Tox-
icity Criteria version 3.0 was used to evaluate toxicity. Dose
modifications were made for grade 3 toxicities, restarting at a
reduced dose (100 mg/d) if toxicities improved to grade 2
within 14 days. Treatment continued until disease progres-
sion, severe or intolerable toxicity, or withdrawal of consent
occurred.
Statistical Analysis
Our primary end point was PFS and the secondary end
point was overall response. WSE analysis was not preplanned
but was considered within the TRUST study. For descriptive
purposes, continuous variables were summarized as arith-
metic means, medians, and standard deviations, and categor-
ical variables comprised proportions with 95% confidence
intervals (95% CI). Inferential comparisons were carried out
by Student’s t or Mann-Whitney U test according to distri-
Arrieta et al. Journal of Thoracic Oncology • Volume 3, Number 8, August 2008
Copyright © 2008 by the International Association for the Study of Lung Cancer888
bution of the data (normal and non-normal) determined by the
Kolmogorov-Smirnov test. 2 or Fisher exact test was used to
assess significance among categorical variables.
Statistical significance was determined as p  0.05
with a two-sided test. Statistically significant and borderline
significant variables (p  0.1) were included in multivariate
logistic regression analysis. PFS was measured from day of
enrollment to the date of last follow-up visit and analyzed
with the Kaplan-Meier technique, whereas comparisons
among subgroups were carried out with the log-rank test. For
analysis of survival curves, all variables were dichotomized.
Adjustment for potential confounders was effected
by multivariate regression analysis. SPSS software pack-
age version 15 (SPSS, Inc., Chicago, IL) was employed for
data analysis.
RESULTS
Patients
A total of 150 patients were included in the study.
Clinical characteristics are summarized in Table 1. Median
age was 64  12 years. Adenocarcinoma was observed in
71%. Tobacco use was reported by 52.3% of patients and
28.2% had WSE with a median exposition of 40  22 years
(4 h/d). Fourteen percent with smoking history had also WSE
and 45% of the non smokers presented WSE. All the patients
except one (caucasic of French nationality) were hispanics.
None of our patients was of Asian origin.
Response
Response was observed in 51 patients (33.8%; 95% CI,
29.9–37.6) according to RECIST criteria (4.3% complete
responses, and 29.5%, partial responses). Stable disease was
achieved in 50 patients (33.3%), and 49 patients (32.6%)
showed progressive disease. Overall response and stable
disease was 67.1%. Clinical subjective improvement and
favorable changes in performance status were observed in 56
and 34% of patients, respectively.
Patients who showed response had greater symptomatic
relief (95.6 versus 35.9%). Table 2 summarizes response
analysis according to clinical and pathologic characteristics.
Factors associated with response to Erlotinib in univariate
analysis included female gender (45 versus 20%; p  0.002),
lack of tobacco use (50 versus 19%; p  0.001), adenocar-
cinoma (35 versus 20%; p  0.085), and WSE (83 versus
13%; p  0.001). Only the histologic type (p  0.05) and
WSE (p  0.001) were of statistical significance in the
logistic regression analysis.
Progression-free Survival
All patients were included in the PFS analysis. Median
follow-up was 4.5 months and median PFS was 7.6 months
(95% CI, 5.3–9.7). PFS-associated clinical and pathologic
characteristics are summarized in Table 3. Factors associated
with longer PFS in univariate analysis comprised adenocar-
cinoma (7.9  0.8 versus 2.3  0.4 months; p  0.001),
female gender (8.4  0.73 versus 5.3  0.96 months; p 
0.025), tobacco use (12.7  2.9 versus 4.9  0.77 months;
p  0.002), ECOG performance status (8.9  2.9 versus
6.5  1.4 months; p  0.058), and WSE (17.6  1.1 versus
5.3  0.9 months; p  0.001). However, in multivariate
analysis only adenocarcinoma (p  0.009) (Figure 1A),
female gender (p  0.04) (Figure 1B), and WSE (p  0.006)
(Figure 1C) showed statistical significance. The median sur-
vival was of 12.4 2.9 months with a 1-year overall survival
of 50% (95% CI, 41–59) and 18.4% at 2 years (95% CI,
41–59). WSE patients had a longer overall survival (19.2 
1.3 months) compared with those with no WSE (7.7  1.2)
(p  0.001).
Toxicity
There were no Erlotinib-related deaths. The most fre-
quent toxicity was rash in 75% of the patients; nevertheless
only 15% presented grade 3 and 4, which required dose
reduction or treatment withdrawal (5%). Grade 1 and 2
diarrhea was present in 30% of the patients.
TABLE 1. Baseline Patient Characteristics
Characteristic No. of patients %
Patients enrolled 150
Gender
Male 70 47
Female 80 53
Age, yr
Median  SD 62.4  12.2
Range 33–88
65 87 57.7
65 63 42.3
ECOG PS
0 10 6.6
1 50 33.3
2 43 28.6
3 47 31.3
Stage at enrollment
IIIB 28 18.4
IV 122 81.6
Histology
Adenocarcinoma 107 71
Other NSCLC 43 29
Smoking status
Non-smokers 72 47.7
Ever-smokers 78 52.3
CNS metastases
Presence 30 20.1
Absence 120 79.9
WSE
Median  SD 40  22
Presence 42 28.2
Absence 108 71.8
Lines of treatment
First 50 33.3
Second 78 52.2
Third 22 14.5
WSE, wood-smoke exposure; CNS, central nervous system; PS, performance status.
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DISCUSSION
In the present study, we found an overall response in
33.8% of patients with NSCLC treated with Erlotinib. This
rate is higher than the documented by other groups who
treated unselected patients with advanced NSCLC with Er-
lotinib.12,20,21 In the interim analysis of compassional use of
Erlotinib, a total of 5908 patients were included.22 Overall
response was reported in 10% of patients with median PFS of
15.1 week, with 12.4 weeks after first-line and 12.7 weeks
after second line chemotherapy.18 This finding suggests that
the clinical characteristics of our cohort are different when
compared with those of previous studies. In our population,
the smoking history was reported in 53%, which is lesser to
that reported in developed countries. However, epidemiologic
studies of NSCLC in Mexico have shown a 66% of smoking-
associated lung cancer.23 It is important to mention that
patients included in this study were not selected based on
their clinical characteristics, but mainly on their assistance to
the pulmonary neoplasms clinic of the hospitals previously
mentioned. These differences could be associated with a
higher overall response. In univariate analysis, we found
similar response predictive factors to those previously re-
ported, such as female gender, adenocarcinoma, and lack of
tobacco use.24–30 Nonetheless, after adjusting for gender,
ECOG status, and histologic type we found that the most
important independent factor associated to both longer sur-
vival and response was WSE, with an overall response of
83.3% and PFS of 17.6 months. In addition, in the absence of
WSE we found response and PFS rates (12.3% and 5.3
months, respectively) similar to what had been previously
reported.12,20,21 It is known that WSE is a risk factor for lung
cancer.31 However, few studies consider this factor in sub-
group analysis, owing the fact that nearly all studies are
performed in developed countries, in which WSE is unusual.
However, our cohort included a high percentage of people
living in rural areas and we found that 28% of patients had
WSE-related NSCLC. In our cohort, the lack of association in
the multivariate analysis of clinical-pathologic factors previ-
ously described in the literature for response and PFS could
be consequence of a strong association between the endpoints
and WSE. The finding that WSE is the most important
independent predictor of PFS and response to Erlotinib treat-
ment has not been previously reported.
The most prominent predictor of somatic mutations in
EGFR is lack of cigarette smoking.32,33 When considering all
geographic and ethnic groups, EGFR mutations are identified
TABLE 2. Relationship Between Clinical Variables and Antitumor Response in Patients
Treated with Erlotinib
Factor
No. of Responses
(complete
and partial)
Overall
Response
Rate (%)
Univariate
Hazard Ratio
(95% CI) p
Multivariate
Hazard Ratio
(95% CI) p
Gender 3.2 (1.5–6.9) 0.002 3.6 (0.7–18) 0.12
Male 15 20.0
Female 36 45.0
Age 1.3 (0.65–2.7) 0.45
65 yr 27 31.0
65 yr 24 38.0
ECOG PS 1.5 (0.7–3.1) 0.32
0–1 17 28.3
2–3 34 37.7
Stage at enrollment 1.6 (0.56–4.8) 0.36
IIIB 7 25.0
IV 44 36.0
Histology 2.7 (0.84–8.9) 0.085 4.8 (1–26) 0.05
Adenocarcinoma 38 35.5
Other NSCLC 9 20.0
Smoking status 4.02 (1.9–8.6) 0.001 1.2 (0.3–5.1) 0.8
Non-smokers 36 50.0
Ever-smokers 15 19.2
CNS metastases 0.9 (0.38–2.2) 0.83
Presence 10 33.3
Absence 41 34.0
WSE 35.4 (12.87–97.4) 0.001 38.1 (9.7–149.7) 0.001
Presence 35 83.3
Absence 14 13.3
Lines of treatment 1.1 (0.5–2.5) 0.75
First 16 32.0
Second/Third 35 35.0
WSE, wood-smoke exposure; CNS, central nervous system; PS, performance status.
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in 51% of never smokers versus 10% of ever smokers.33,34
Preliminary data have suggested that patients with lung can-
cer with tumors displaying EGFR-TK domain mutations
respond better to Erlotinib than those without such muta-
tions.34 In addition, K-Ras mutations are reported to occur in
30 to 50% of patients with tobacco-associated adenocarci-
noma of lung,31 and K-Ras mutation is associated with lack of
response to Erlotinib.18 These data strongly support the no-
tion that lung tumorigenesis proceeds through different mo-
lecular mechanisms according to smoking status.35 Current
evidence indicates that lung cancer in never smokers or lung
cancer associated with other risk factors such as WSE con-
stitute a distinct disease entity with unique molecular and
biologic characteristics.
It is known that there are significant changes in Erlo-
tinib pharmacokinetic in smokers compared with non smok-
FIGURE 1. Kaplan-Meir plots of PFS for patients receiving Erlotinib treatment classified according to (A) histology, (B) gen-
der, and (C) WSE status.
TABLE 3. Survival Analysis
Factor Median  SE Univariate Analysis (p)
Multivariate Analysis
Hazard
Ratio 95% CI p
Sex 0.025 0.54 0.3–0.97 0.04
Male 5.3  0.96
Female 8.4  0.73
Age 0.62
65 yr 7.6  1.6
65 yr 7.4  1.4
ECOG PS 0.058 1.6 0.9–2.9 0.106
0–1 8.9  2.9
2–3 6.5  1.4
Stage at enrollment 0.77
IIIB 8.4  2.7
IV 7.0  1.2
Histology 0.001 0.45 0.25–0.81 0.009
Adenocarcinoma 7.9  0.8
Other NSCLC 2.3  0.4
Smoking status 0.002 1.05 0.5–2.02 0.871
Non-smokers 12.7  2.9
Ever-smokers 4.9  0.77
CNS metastases 0.58
Presence 7.3  1.6
Absence 6.6  1.2
WSE 0.001 0.36 0.18–0.75 0.006
Presence 17.6  1.11
Absence 5.3  0.9
Lines of treatment 0.63
First 5.3  1.7
Second/third 7.6  0.9
WSE, wood-smoke exposure; CNS, central nervous system; PS, performance status.
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ers with a significant decrease in area under the curve,
possibly because of an induction of cytochrome P450
(CYP3A4 and CYP3A5).36,37 Nevertheless, there is no infor-
mation about differences in clearance of Erlotinib or Ge-
fitinib. WSE in contrast to cigarette smoking does not induce
the activity or expression of cytochromes at pulmonary level
in rats.38 So it is unlikely that WSE could affect Erlotinib
clearance and explain our results.
In relation to central nervous system metastasis, there
have been reports about response to Erlotinib treatment when
EGFR mutation is present, which suggest that inhibitors of
EGF-receptor TK are capable of penetrating the blood–brain
barrier in presence of cerebral metastasis. This could explain
the absence of poor prognosis related with cerebral metastasis
when patients were treated with Erlotinib.39,40
Limited data are available on the etiopathogenesis,
molecular abnormalities, and prognosis of WSE-related
NSCLC; nevertheless, the association between WSE and
better response and PFS suggests that carcinogenic mecha-
nisms in NSCLC involve EGFR and/or absent K-Ras muta-
tions. Molecular studies in signaling pathways related with
EGFR and K-Ras in patients with WSE-associated NSCLC
are warranted. In conclusion, patients with WSE-related
NSCLC have a high probability of response to Erlotinib with
a higher PFS.
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